ARTICLE | Clinical News
Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors
June 25, 2018 8:59 PM UTC
Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on solid tumor indications where it sees larger market opportunities.
Erytech lost €4.77 (31%) to €10.90 on Euronext and was down $5.20 (29%) to $12.75 on NASDAQ...
BCIQ Company Profiles